Status of acute symptomatic attacks in a female patient with thyrotoxicosis: Hashimoto’s encephalopathy. Case report

Cover Page

Abstract

Hashimoto’s Encephalopathy is an autoimmune disease associated with significant increase in titer of autoantibodies to thyroid peroxidase and thyroglobulin and characterized by inflammatory and degenerative brain disorders. We report a clinical case of recurrent status of acute symptomatic attacks in a female patient with Hashimoto’s encephalopathy.

About the authors

Yu. V. Tokareva

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

A. S. Kotov

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Author for correspondence.
Email: alex-013@yandex.ru
Russian Federation, Moscow

E. I. Semenova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

Yu. V. Eliseev

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

M. V. Romanova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

M. A. Alakova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

I. V. Misnikova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

I. V. Komerdus

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
Russian Federation, Moscow

References

  1. Аникина М.А., Муравьев О.Б., Сотников А.С., Левин О.С. Энцефалопатия Хашимото. Журн. неврол. и психиатр. 2012; 10 (2): 33–38.
  2. Филиппов П.П. Паранеопластические антигены и ранняя диагностика рака. Соросовский образоват. журн. 2000; 6 (9): 3–9.
  3. Шнайдер Н.А., Дмитренко Д.В., Дыхно Ю.А. Ежикова В.В. Проблемы диагностики паранеопластического лимбического энцефалита. Журн. Эпилепсия и пароксизмальные состояния. 2013; 3 (5): 49–58.
  4. Anand K.S, Garg J., Verma R., Chakraborty A. Hashimoto’s Encephalitis:Unusual Cause of Reversible Dementia. J Family Med Prim Care 2014; 3 (3): 284–286. doi: 10.4103/2249-4863.141650. PMID: 25374873.
  5. Bismilla Z., Sell E., Donner E. Hashimoto encephalopathy responding to risperidone. J Child Neurol. 2007; 22: 855. doi: 10.1177/0883073807304202. PMID: 17715278.
  6. Blanchin S., Coffin C., Viader F. et al. Anti-thyroperoxidase antibodies from patients with Hashimoto’s encephalopathy bind to cerebellar astrocytes. J Neuroimmunol. 2007; 192: 13–20. doi: 10.1016/j.jneuroim.2007.08.012. PMID: 17963848.
  7. Brain L., Jellinek E.H., Ball К. Hashimoto’s disease and encephalopathy; Lancet 1966; 2: 512–514. doi: 10.1016/S0140-6736(66)92876-5. PMID: 4161638.
  8. Buckley C., Oger J., Clover L. et al. Potassium channel antibodies in two 25 patients with reversible limbic encephalitis. Ann. Neurol. 2001; 50: 73–78. doi: 10.1002/ana.1097. PMID: 11456313.
  9. Castillo P., Woodruff B., Caselli R. et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63: 197–202. doi: 10.1001/archneur.63.2.197. PMID: 16476807.
  10. De Holanda N.C., de Lima D.D., Cavalcanti T.B. et al. Hashimoto’s encephalopathy: systematic review of the literature and an additional case. J Neuropsychiatry Clin Neurosci. 2011; 23 (4): 384–390. doi: 10.1176/jnp.23.4.jnp384. PMID: 22231308.
  11. Ferracci F., Bertiato G., Moretto G. Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci. 2004; 217(2): 165–168. doi: 10.1016/j.jns.2003.09.007. PMID: 14706219.
  12. Fujii A., Yoneda M., Ito T. et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J Neuroimmunol. 2005; 162: 130–136. doi: 10.1016/j.jneuroim.2005.02.004. PMID: 15833368.
  13. Gliebus G., Lippa C.F. Cerebrospinal immunoglobulin level changes and clinical response to treatment of Hashimoto’s encephalopathy. Am J Alzheimer’s Dis Other Demen. 2009; 24 (5): 373–376. doi: 10.1177/1533317509339162. PMID: 19561326.
  14. Henchey R., Cibula J., Helveston W. et al. Electroencephalographic findings in Hashimoto’s encephalopathy. Neurology 1995; 45: 977–981.doi: 10.1212/WNL.45.5.977. PMID: 7746418.
  15. Irani S.R., Bera K., Waters P. et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133 (6): 1655–1667. doi: 10.1093/brain/awq113. PMID: 20511282.
  16. Dalmau J., Gleichman A.J., Hughes E.J. et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. The Lancet Neurology 2008; 7 (12): 1091–1098. doi: 10.1016/S1474-4422(08)70224-2. PMID: 18851928.
  17. Kothbauer-Margreiter I., Sturzenegger M., Komor J. et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996; 243: 585–593. doi: 10.1007/BF00900946. PMID: 8865025.
  18. Lalani N., Haq R. Prognostic effect of early treatment of paraneoplastic limbic encephalitis in a patient with small-cell lung cancer. Curr. Oncol. 2012; 19: 353–357. doi: 10.3747/co.19.1007. PMID: 23144583.
  19. Marshall G.A., Doyle J. Long-term treatment of Hashimoto’s encephalopathy. The Journal of Neuropsychiatry and Clinical Neurosciences 2006; 18: 14–20. doi: 10.1176/jnp.18.1.14. PMID: 16525066.
  20. Martin Т., Torres A., Gentil A. et al. Role of brain single photon emission computed tomography in the diagnosis of distinct forms of presentation of Hashimoto’s encephalopathy. Endocrinol Nutr. 2009; 56 (6): 344–347. doi: 10.1016/S1575-0922(09)71950-3. PMID: 19695517.
  21. Nieuwenhuis L., Santens P., Vanwalleghem P., Boon P. Subacute Hashimoto’s encephalopathy, treated with plasmapheresis. Acta Neurol Belg. 2004; 104: 80–83. PMID: 15508271.
  22. Prüss H., Dalmau J., Harms L. et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010; 75 (19): 1735–1739. doi: 10.1212/WNL.0b013e3181fc2a06. PMID: 21060097.
  23. Sapkota S.K., Sapkota B.L., Pitiyanuvath N. Hashimoto Encephalopathy or Neurosarcoidosis? A Case Report. Neurohospitalist 2015; 5(2): 70–73. doi: 10.1177/1941874414554299. PMID: 25829987.
  24. Song Y.M., Seo D.W., Chang G.Y. MR findings in Hashimoto encephalopathy. AJNR Am J Neuroradiol. 2004; 25: 807–808. PMID: 15140725.
  25. Titulaer M.J., McCracken L., Gabilondo I. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. The Lancet Neurology 2013; 12 (2): 157–165. doi: 10.1016/S1474 4422(12)70310-1. PMID: 23290630.
  26. Tsai M.H., Lee L.H., Chen S.D. et al. Complex partial status epilepticus as a manifestation of Hashimoto’s encephalopathy. Seizure 2007; 16: 713–716. doi: 10.1016/j.seizure.2007.05.018. PMID: 17600734.
  27. Watemberg N., Greenstein D., Levine A. Encephalopathy associated with Hashimoto thyroiditis: pediatric perspective. J Child Neurol. 2006; 21: 1–9. PMID: 16551444.
  28. Wong L.C., Freeburg J.D., Montouris G.D., Hohler A.D. Two patients with Hashimoto’s encephalopathy and uncontrolled diabetes successfully treated with levetiracetam. J Neurol Sci. 2015; 348 (1–2): 251–252. doi: 10.1016/j.jns.2014.11.007. PMID: 25467138.
  29. Yoneda M., Fujii A., Ito A. et al. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto’s encephalopathy. J Neuroimmunol. 2007; 185: 195–200. doi: 10.1016/j.jneuroim.2007.01.018. PMID: 17335908.

Statistics

Views

Abstract: 1168

PDF (Russian): 1133

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2016 Tokareva Y.V., Kotov A.S., Semenova E.I., Eliseev Y.V., Romanova M.V., Alakova M.A., Misnikova I.V., Komerdus I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies